Exubera

11/01/2005 - "Furthermore, Exubera has shown clinical superiority to oral agent regimens in patients with type 2 diabetes who failed to achieve their target HbA1c using lifestyle modification and oral agents. "
11/01/2005 - "The results of these trials, and others, suggest that Exubera may be a valuable tool to help a wide variety of patients with type 1 or type 2 diabetes reach their recommended goals for glycaemic control, irrespective of their current therapy."
05/01/2005 - "Efficacy has also been demonstrated for Exubera when used as adjunctive therapy with oral medications for type 2 diabetes. "
09/01/2008 - "Two-year pulmonary safety and efficacy of inhaled human insulin (Exubera) in adult patients with type 2 diabetes."
09/01/2008 - "The purpose of this study was to evaluate the 2-year pulmonary safety of inhaled human insulin (Exubera [EXU]) in 635 nonsmoking adults with type 2 diabetes. "

06/01/2002 - "Aventis, Pfizer develop Exubera to treat type 1 diabetes."
03/01/2007 - "Two-year safety and efficacy of inhaled human insulin (Exubera) in adult patients with type 1 diabetes."
06/01/2008 - "Efficacy and safety of inhaled human insulin (Exubera) compared to subcutaneous insulin in children ages 6 to 11 years with type 1 diabetes mellitus: results of a 3-month, randomized, parallel trial."
11/01/2005 - "Several phase 3 studies of 24-week duration have demonstrated comparable glycosylated haemoglobin (HbA1c) control in patients with type 1 diabetes treated with Exubera vs. SC insulin. "
06/01/2008 - "To compare the efficacy and safety of Exubera (EXU) with subcutaneous (SC) insulin in children, ages 6-11 years, with type 1 diabetes mellitus. "

07/01/2008 - "The treatment effects on lung function observed in Exubera trials are not caused by lung inflammation."
07/01/2008 - "Therefore, 12 weeks of Exubera treatment is not associated with evidence of pulmonary inflammation. "

01/01/2019 - "Lung Cancer-Related Mortality With Inhaled Insulin or a Comparator: Follow-Up Study of patients previously enrolled in Exubera Controlled Clinical Trials (FUSE) Final Results."
01/01/2019 - "The Follow-Up Study of patients previously enrolled in Exubera controlled clinical trials (FUSE) was designed to evaluate whether patients previously treated with Exubera (EXU; insulin human [rDNA origin], inhaled powder) in controlled clinical trials died because of incident primary lung cancer at a substantially higher rate than patients treated with a comparator. "

07/01/2008 - "The present study assessed whether changes occur in cellular and soluble constituents of airway lining fluid consistent with inflammation as a possible cause for Exubera-associated lung function alterations. "